BrainStorm Cell Therapeutics Inc (BCLI)

[mybikeisorange]

In case you missed it, here is the data presented by the private company Genervon from their Phase 2a trial. At first glance it is very positive and was likely responsible for the Cur and BCLI sell yesterday:

http://www.businesswire.com/news/home/20141019005074/en/Genervon-Announces-ALS-PD-Phase-2a-Trial#.VEZOlIvLdFk

I said at first glance because I did some digging into Genervon's data and found some important things that I think clearly change the strength of their data and it was interpreted by the market.

I posted the same thing at Yahoo and thebiotechinvestor, but here is the cliff's notes version. I'll try to post a more detailed version in a bit:

The Genervon ALS Phase 2a trial was a simple pilot study which seems to have been done as a "one-tailed" study. They mentioned "one-tailed" in the PR and most pilot studies, where they are simply just trying to test a hypothesis, are one-tailed. One-tailed trial data will have greatly inflated numbers as it is only measuring one direction of the effect of treatment. Where as a two-tailed trial (what BCLI and CUR are doing) measures both directions and therefore the numbers are lower.

I think it is pretty clear that this is the case with Genervon's trial data, but would of course appreciate anyone to look at it my "analysis" which I'll try and post below, and punch holes in it.